Filing Flows › Alamar Biosciences (ALMR) › Q3 2026 › vs Q2 2026
Alamar Biosciences (ALMR) Q3 2026 vs Q2 2026 (quarter over quarter)
Alamar Biosciences's revenue rose $4.1M (+14%) from $29.4M in Q2 2026 to $33.5M in Q3 2026. The biggest changes: Product +$3.0M (+13%); Service Other +$1.1M (+18%).
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $17.8M | $15.5M | $2.4M | +15% |
| Instruments | $8.5M | $7.8M | $680K | +9% |
| Product | $26.3M | $23.3M | $3.0M | +13% |
| Service Other | $7.2M | $6.2M | $1.1M | +18% |
| Revenue | $33.5M | $29.4M | $4.1M | +14% |
| Other income, net | $1.9M | $240K | $1.7M | +688% |
| Net loss | $13.3M | $13.2M | $143K | +1% |
| Costs & expenses | $48.8M | $43.0M | $5.8M | +14% |
| Operating costs | $48.7M | $43.0M | $5.7M | +13% |
| Income tax | $94K | −$93K | $187K | — |
| Cost of revenue | $12.9M | $11.7M | $1.2M | +10% |
| Research & development | $16.2M | $13.8M | $2.4M | +17% |
| SG&A | $19.6M | $17.4M | $2.2M | +13% |
| Operating cash sources | $20.1M | $15.7M | $4.3M | +28% |
| Depreciation & amortization | $1.4M | $1.1M | $290K | +26% |
| Share-based compensation | $3.9M | $3.3M | $636K | +19% |
| Cash used in operations | $14.7M | $11.3M | $3.4M | +30% |
| Net loss absorbed | $13.3M | $13.2M | $143K | +1% |
| Working capital & other | $6.7M | $2.5M | $4.2M | +165% |
Questions
How much did Alamar Biosciences's revenue grow quarter over quarter in Q3 2026?
Alamar Biosciences's revenue rose $4.1M (+14%) from $29.4M in Q2 2026 to $33.5M in Q3 2026.
What drove Alamar Biosciences's revenue change in Q3 2026?
Product +$3.0M (+13%); Service Other +$1.1M (+18%).